Biostar Pharmaceuticals Inc (BSPM) Financial Statements (2024 and earlier)

Company Profile

Business Address NO. 588 SHIJI XI AVENUE
XIANYANG, SHAANXI PROVINCE, 712046
State of Incorp. MD
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2017
MRQ
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 173391,685801,759
Cash and cash equivalents 173391,685801,759
Receivables 7,02515,89427,0811,84631,362
Inventory, net of allowances, customer advances and progress billings 167235674830847
Inventory 167235674830847
Prepaid expense 0 4,072 
Advances on inventory purchases    654 
Prepaid expense and other current assets7,741
Income taxes receivable375265
Other undisclosed current assets   10,12132,200 
Total current assets: 7,36516,16743,63335,98641,974
Noncurrent Assets
Property, plant and equipment 5,8676,8118,4837,7296,981
Intangible assets, net (including goodwill) 5,6076,87913,27017,1349,136
Intangible assets, net (excluding goodwill) 5,6076,87913,27017,1349,136
Prepaid expense    3,927
Deposits noncurrent assets 21,14816,1008,7953,9278,718
Other undisclosed noncurrent assets 2,5155,4077,06634,84845,640
Total noncurrent assets: 35,13735,19637,61467,56470,475
TOTAL ASSETS: 42,50251,36481,247103,550112,449
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 2,8424,2665,434344630
Taxes payable  113433344630
Accounts payable 2,8424,1535,001  
Debt 2,3262,7733,095 4,755
Derivative instruments and hedges, liabilities 45559383  
Due to related parties     1,585
Other undisclosed current liabilities    4,4475,732
Total current liabilities: 5,6237,0988,9124,79212,703
Noncurrent Liabilities
Total liabilities: 5,6237,0988,9124,79212,703
Equity
Equity, attributable to parent, including: 36,87944,26572,33562,77357,773
Common stock 32151310
Additional paid in capital 31,38230,31730,30425,74923,267
Deferred compensation equity    (365) 
Accumulated other comprehensive income 6813,4346,3926,6004,529
Retained earnings (accumulated deficit) (2,541)3,15728,27023,65023,230
Other undisclosed equity, attributable to parent 7,3547,3547,3547,1266,737
Total equity: 36,87944,26572,33562,77357,773
TOTAL LIABILITIES AND EQUITY: 42,50251,36481,24767,56470,475

Income Statement (P&L) ($ in thousands)

9/30/2017
TTM
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)
 2,38427,13061,41752,72949,318
Cost of revenue
(Cost of Goods and Services Sold)
 (1,469)(16,026)(31,140)(27,046)(19,467)
Gross profit: 91511,10430,27625,68329,851
Operating expenses (4,479)(34,862)(31,589)(25,175)(51,637)
Operating income (loss): (3,564)(23,758)(1,313)508(21,786)
Nonoperating income (expense) 519(35)2,8472,148212
Investment income, nonoperating 191,3301,345296
Other nonoperating income (expense) 497(85)1,09421
Interest and debt expense (206)(284)(155)(367)(84)
Other undisclosed income from continuing operations before equity method investments, income taxes 20628415536784
Income (loss) from continuing operations before income taxes: (3,045)(23,793)1,5352,656(21,574)
Income tax expense (benefit) (2,653)(1,320)3,314(1,847)1,576
Income (loss) from continuing operations: (5,698)(25,113)4,848809(19,997)
Income (loss) before gain (loss) on sale of properties: (5,698)(25,113)4,848809(19,997)
Net income (loss) available to common stockholders, diluted: (5,698)(25,113)4,848809(19,997)

Comprehensive Income ($ in thousands)

9/30/2017
TTM
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net income (loss): (5,698)(25,113)4,848809(19,997)
Other comprehensive loss   (208)  
Comprehensive income (loss): (5,698)(25,113)4,640809(19,997)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (2,754)(2,958) 2,072547
Comprehensive income (loss), net of tax, attributable to parent: (8,452)(28,070)4,6402,881(19,451)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: